

Northcape Capital Concentrated Australian Equities

Fund Profile

June 2023



Concentrated Australian Equities | Fund Profile

Performance (Gross, % per annum):

Concentrated Australia Equities	Month	3 Months	1 Year	3 Years	5 Years	10 Years	Since Inc.
Fund Performance	0.72	0.80	15.81	12.77	8.83	10.20	9.31
Benchmark	1.73	0.99	14.40	11.07	7.12	8.55	6.93
Relative Return	-1.01	-0.19	+1.42	+1.70	+1.70	+1.65	+2.38

Inception date of the Northcape Capital Concentrated Australian Shares composite is 1 Apr 2005. Returns shown are gross of fees and taxes.


Cumulative Performance (Gross, %):



Fund Details:

Objective:	Outperform the benchmark over a rolling 3 to 5 year basis.	
Benchmark:	S&P / ASX 300 Accumulation Index	
Type of Investor:	Wholesale / Institutional only	
Investment Options:	Separate Mandate	
Fund Inception:	Nov 2005	
AUM A\$bn:	\$3.9 billion	

Sector Allocation (%):



Characteristics:

Number of Stocks:	25		
Portfolio Dividend Yield:	3.7%		
Stock Range:	20-25		
Sector Range:	unconstrained		
Cash Range:	0-5%		
Portfolio Turnover:	20-30%		

Concentrated Australian Equities | Fund Profile

Investment Philosophy and Process

Northcape adopts a long term approach to investing and believes that superior investment returns rely on fundamental research, good judgement and experience.

Rigorous in-house research is the basis of our investment process. Industry sectors have been divided more or less equally amongst the investment team, although there is freedom for any member to cover a particular stock in the investment universe. Each analyst decides which stocks to undertake work on within their coverage. There are no rules or constraints placed on the analyst and his/her research methodology. The primary focus is to identify quality businesses that offer above average growth prospects and high rates of return on equity over the long term.

This research process filters the investable universe to a list of investment grade companies, which we call our Approved List. In order to get a stock on the Approved List, the analyst has to present a detailed research paper to the investment team. Unanimous agreement is required for approval. The Approved List is dynamic, and reflects our selection of the highest quality businesses regardless of pricing. In the development of the Approved List, information and research are pooled and debated intensively. There is regular review of the stocks on the Approved List. This reinforces the peer review approach, broadens knowledge through collective learning and, requires us to monitor the market for new information and views.

From this Approved list, a concentrated investment portfolio is constructed. These stocks are picked with

reference to value and risk/reward skew. We assess whether risk outcomes for companies are symmetric or asymmetric. For some companies the risk to profit could skew heavily to the downside under certain scenarios while upside risk may be relatively modest. It is important to assess both relative valuation and risk/ reward skew when constructing the portfolio.

At Northcape we use a multiple portfolio manager approach as we believe this is the optimal structure for experienced portfolio managers to focus on their best investment ideas. Under this approach the timing of decisions and portfolio weightings is delegated to individual portfolio managers who are responsible for managing a segment of the overall portfolio. Each portfolio manager has ultimate accountability for ensuring that their highest conviction ideas are included in their slice of the portfolio.

As portfolio managers, the team members are free, within the strict constraints of the client mandates and the Approved List, to exercise their investment skills to the maximum. There are no committee decisions in this phase.

We do not set portfolio weightings relative to the composition of the index. Stock and sector exposures are an outcome of our portfolio construction process. A **diagram of our investment process** is provided below:

Approved list

- The investable universe is filtered to a list of investment grade companies, which we call our Approved List.
- We eliminate companies that are considered financially risky and/or have weak governance structures.

In-house research

Minimal reliance on brokers.

.

.

- Northcape has a large number of experienced analysts and a large travel allowance.
- Analysts are encourage to make regular site visits to companies, competitors and regulatory bodies.
- A range of valuation measures are used.

Discussion & debate

Forums:

- Morning meetings
- Rolling review of Approval List.

Process:

- Debate views.
- Consider different scenarios.
- Risk / reward considerations

Multi PM approach

Portfolio construction

- Individual judgment. PM's choose stocks from the Approved List according to their own style, valuation methodology and experience.
- High conviction, concentrated portfolios.
- Concentrated fund typically 20-25 stocks held.

Concentrated Australian Equities | Fund Profile

June 2023

Australian Equity Investment Team:



Rob Inglis Director | Portfolio Manager | Analyst

44 years investment experience



Craig McCourtie Director | Portfolio Manager | Analyst

37 years investment experience



Richard Maynier Portfolio Manager | Analyst

20 years investment experience

Kevin Soo Senior Analyst 10 years investment experience



Paul Parsons Portfolio Manager | Analyst

23 years investment experience



Peiting Liang Analyst 8 years investment experience

Contact:

Katie Orsini

Client Director P: +61 2 8234 3629 E: katie.orsini@northcape.com.au

Wendy Hammond

Senior Manager, Client Development P: +61 2 8234 3638 E: wendy.hammond@northcape.com.au

Important information: The Northcape Capital Concentrated Australian Equities strategy is available for investment only to wholesale investors. While the information contained in this fund profile has been prepared with all reasonable care, Northcape Capital accepts no responsibility or liability for any errors, omissions or misstatements however caused. No action has been taken to register or qualify this product or otherwise permit a public offering of this product in any jurisdiction outside Australia. Persons outside Australia should consult their professional advisers as to whether any governmental or other consents are required or other formalities need to be observed to enable them to invest in this product. Performance data is for the Northcape Concentrated Australian Equity Composite. Past performance is not indicative of future performance.

Sydney

Level 24, 45 Clarence Street Sydney NSW 2000 Australia

P: +61 2 8234 3600

Melbourne

Level 18, 90 Collins Street Melbourne VIC 3000 Australia

P: +61 3 8626 8000

ABN: 53 106 390 247

AFSL: 281767